Study details
Enrolling now
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
AbbVie
NCT IDNCT07514260ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–65
Locations
1 site in CA
About this study
This Phase 1 study is focused on people with healthy volunteers. The primary outcome being measured is Number of Participants with Adverse Events (AEs).
Based on ClinicalTrials.gov records.
PhasePhase 1
Primary goalNumber of Participants with Adverse Events (AEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of Participants with Adverse Events (AEs)